Following a period of significant volatility, trading in Tilray Brands shares showed marked stabilization in the latest session. The stock closed at approximately $10.58, navigating a narrow band throughout the day. This price action suggests a shift in market focus from short-term headline noise to the medium-term implications of revised U.S. cannabis regulations.
- Previous Close: $10.58
- Daily Trading Range: $10.50 to $10.58
- Bernstein SocGen Price Target: $10.00 (raised from $1.00)
- Next Earnings Report: January 8, 2026
Market Calm Follows Regulatory Shift
The recent price swings were triggered by the White House confirmation on December 18 that it would reschedule cannabis from Schedule I to Schedule III via an executive order. This announcement propelled the stock to an intraday high near $12.34 on December 19, before a substantial pullback ensued. By Monday’s close, the share price had retreated nearly 15% from that peak.
Monday’s session ended with shares at $10.42. The subsequent day’s trading was notably quieter, confined to a tight eight-cent range. This consolidation indicates that the initial selling pressure following the news has largely subsided.
Valuation and Analyst Perspective
Despite the sharp correction, analyst sentiment is not uniformly negative. Bernstein SocGen Group significantly revised its outlook for Tilray on Friday, lifting its price target to $10.00 from $1.00. The firm cited an improved risk profile under the anticipated Schedule III classification as the rationale.
With the stock trading just above this new target, the current valuation is seen to already incorporate a substantial portion of the expected regulatory benefits. This level may represent a new foundational valuation benchmark from the analyst’s viewpoint.
Should investors sell immediately? Or is it worth buying Tilray?
Tax Code Change as a Primary Catalyst
A central element of the reassessment is the potential neutralization of Section 280E of the U.S. tax code. Currently, Tilray and similar companies are effectively taxed on gross profit rather than net income. The move to Schedule III is expected to eventually end this disparate treatment.
For Tilray, the impact could be material: a normalized tax burden would likely free up additional cash flow. These funds could be deployed to support the company’s expanding U.S. beverage and wellness operations. Market observers note, however, that implementing the new rules will be a process, making the precise timeline a critical factor.
The company’s diversified portfolio, including interests in craft beer and hemp, has provided stability during previous regulatory uncertainty. Nonetheless, the stock’s performance remains highly sensitive to U.S. federal policy developments.
Forward Focus and Technical Levels
Attention is now turning more squarely to operational performance. Tilray is scheduled to release its next quarterly results on January 8, 2026. Management will likely offer initial details on the projected timing and financial impact of the rescheduling.
From a chart perspective, the zone between $10.00 and $10.40 is viewed as a crucial support area for the medium-term trend. A sustained drop below $10.00 could see the stock re-enter single-digit territory. Conversely, a climb above the $11.50 level would suggest the recent corrective phase is complete, providing technical confirmation of the initial bullish impulse from the executive order.
Ad
Tilray Stock: Buy or Sell?! New Tilray Analysis from December 24 delivers the answer:
The latest Tilray figures speak for themselves: Urgent action needed for Tilray investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from December 24.
Tilray: Buy or sell? Read more here...
